NCT04710030View on ClinicalTrials.gov

Valacyclovir for Mild Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 23, 2024

Study Completion Date

December 23, 2024

Conditions
Mild Cognitive ImpairmentHerpes Simplex 1Herpes Simplex 2
Interventions
DRUG

Valacyclovir hydrochloride 500mg caplet

Active Comparator

DRUG

Placebo sugar pill caplet

Placebo Comparator

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT04710030 - Valacyclovir for Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter